Characteristics of splenectomized patients
. | Controls (n = 8) . | ITP (n = 13) . | P . |
---|---|---|---|
Age, y | 54.4 (26.9-65.8) | 27.5 (22-52) | .1 |
Gender ratio (female/male) | 3/5 | 11/2 | .06 |
Platelet count, ×109/L | 191 (167-253) | 22.5 (17-27) | .0002 |
Disease duration, mo | — | 19.8 (11.9-42) | |
Previous treatments, n (%) | |||
Steroids | — | 13 (100) | |
IVIg | — | 9 (69.2) | |
Dapsone | — | 8 (61.5) | |
Treatment within the 2 wk prior to splenectomy, n (%) | |||
IVIg | — | 8 (61.5) | |
Steroids | — | 3 (23.1) | |
Dapsone | — | 1 (7.7) | |
None | — | 1 (7.7) | |
Responder to splenectomy, n (%) | 12 (92.3) |
. | Controls (n = 8) . | ITP (n = 13) . | P . |
---|---|---|---|
Age, y | 54.4 (26.9-65.8) | 27.5 (22-52) | .1 |
Gender ratio (female/male) | 3/5 | 11/2 | .06 |
Platelet count, ×109/L | 191 (167-253) | 22.5 (17-27) | .0002 |
Disease duration, mo | — | 19.8 (11.9-42) | |
Previous treatments, n (%) | |||
Steroids | — | 13 (100) | |
IVIg | — | 9 (69.2) | |
Dapsone | — | 8 (61.5) | |
Treatment within the 2 wk prior to splenectomy, n (%) | |||
IVIg | — | 8 (61.5) | |
Steroids | — | 3 (23.1) | |
Dapsone | — | 1 (7.7) | |
None | — | 1 (7.7) | |
Responder to splenectomy, n (%) | 12 (92.3) |